SLC5A2 and type 2 diabetes mellitus: According to a report generated by the Food and Drug Administration (FDA), seventy-three cases of ketoacidosis requiring hospitalization were reported from March 2013 to May 2015 in patients with type 1 or type 2 diabetes mellitus treated with SGLT2 inhibitors; however, out of 73 cases, 40 had an average blood glucose levels of 11.7 mmol/L (211 mg/dL).